Clinical Trial Update: Triac Trial II in MCT8 Deficiency Patients [Phase 2]

View source ↗

Summary

Phase 2 trial (Triac Trial II) evaluating tiratricol for Allan-Herndon-Dudley Syndrome is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allan-herndon-dudley Syndrome

Drugs mentioned

• Triac (tiratricol)

Snippet

Sponsor: Rare Thyroid Therapeutics International AB | Conditions: Allan-Herndon-Dudley Syndrome | Phase 2 | Status: ACTIVE_NOT_RECRUITING